Single-program concentration
PBFT02 is currently the only clinical-stage product candidate, so setbacks would have outsized impact.
- Scope
- Pipeline concentration
- Materiality
- high
Passage BIO, Inc.
Passage BIO, Inc. is a U.S.-based clinical-stage genetic medicines company focused on developing one-time gene therapies for neurodegenerative diseases. The company was incorporated in Delaware and is centered on advancing licensed technology, conducting clinical trials, and manufacturing clinical supply for its product candidates.
2.07
2.07
| % | |
|---|---|
| Clinical-stage gene therapy candidates | 0% One-time genetic medicines designed to treat neurodegenerative diseases, including PBFT02. |
| Preclinical and translational development | 0% Research, assay development, and preclinical studies supporting pipeline advancement. |
| Clinical trial supply and manufacturing | 0% Manufacturing of clinical-grade material and supply for ongoing trials. |
| Licensed technology development | 0% Development and use of in-licensed intellectual property for CNS gene therapy programs. |
Passage BIO’s direct customers are not commercial end-users today; its work is aimed at regulators, clinical...
- Clinical investigators and trial sitesprimary
They run studies of PBFT02 and related programs and need clinical supply, protocols, and support.
- Regulatorsprimary
FDA and other agencies evaluate the company’s clinical and manufacturing data for approval pathways.
- Future patients with neurodegenerative diseaseprimary
The eventual end users of approved gene therapies for CNS disorders such as frontotemporal dementia.
- Potential strategic partnerssecondary
Biopharma collaborators or licensors that may support development, funding, or commercialization.
Passage BIO is incorporated in Delaware and operates as a U.S.-based development-stage biotechnology company...
- •Incorporated in Delaware, United States
- •Clinical development and operations are U.S.-based
- •Manufacturing supply currently relies on third-party U.S. facilities
- •Future market access would depend on U.S. and international reimbursement
- •No country revenue disclosure is available because the company is pre-commercial
The company’s strategy is to advance PBFT02 and other gene therapy programs through clinical development, with a focus...
01
Advance PBFT02 clinical developmentshort-term
Clinical data are the main driver of value for a pre-commercial gene therapy company.
02
Secure additional capitalshort-term
Development-stage operations require external funding before product revenue exists.
03
Strengthen manufacturing and assay capabilitiesmedium-term
Gene therapies require validated, reproducible manufacturing and release testing.
Passage BIO faces the typical risks of a clinical-stage biotechnology company: clinical failure, regulatory delay,...
Clinical development failure
Gene therapy programs can fail on safety, efficacy, dosing, or delivery even after early promise.
- Scope
- PBFT02 and CNS gene therapy platform
- Materiality
- high
Manufacturing and supply chain disruption
The company relies on third parties for clinical supply, testing, and process development.
- Scope
- Catalent Maryland and external labs
- Materiality
- high
Financing risk
Operations are funded through external capital until product revenue, if any, is generated.
- Scope
- Equity, debt, collaborations
- Materiality
- high
Reimbursement and market access risk
Even if approved, payors may limit coverage or pricing for high-cost gene therapies.
- Scope
- U.S. and international commercialization
- Materiality
- medium
Research and development expense recognition
Clinical trial, manufacturing, and development costs
Accruals for clinical and manufacturing vendors
Operating expenses and liabilities
Impairment of licensed technology or intangibles
Balance sheet carrying values and earnings
Stock-based compensation
Operating expense and diluted share count
: 29.4.2026